Can You Still Get a COVID Shot in 2026 Under the New FDA Rules?
Yes, if you're 65 or older, or you have any of the CDC's high-risk conditions. That list includes diabetes, obesity, heart or lung disease, kidney disease, cancer, immunocompromise, pregnancy, and even current or former smoking. Most American adults still qualify. The FDA moved from a universal recommendation to a risk-based one, and the risk category is wide.
The new label is narrower than it sounds. On August 27, 2026, the FDA approved four updated shots for the 2026-2027 season, all targeting the JN.1-lineage XFG subvariant: Pfizer's Comirnaty, Moderna's Spikevax and mNEXSPIKE, and the protein-based Novavax Nuvaxovid. All four are approved for adults 65 and older, and for anyone under 65 with a condition that raises the risk of severe COVID. Doses began shipping the same day. If you're a healthy adult under 65 with no such condition, the shot isn't FDA-approved for you this season.
The boundary of the new rule is that phrase, high-risk condition. So the question is who counts.
What CDC counts as high-risk
The list is wide. Cancer. Chronic kidney, liver, or lung disease, including asthma. Heart disease. Type 1 or Type 2 diabetes. Being immunocompromised. A BMI of 30 or above. Pregnancy or recent pregnancy. Sickle cell disease. Stroke. Transplant. Physical inactivity. Current or former smoking. Any one is enough.
That's a wide enough net that most American adults under 65 land inside it, whether from having smoked, a BMI above 30, or one of the more common chronic diseases. The FDA label defers to the CDC's list rather than publishing its own, so the working definition of high-risk in 2026 is whatever the CDC counts as a severe-COVID risk factor.
| Vaccine (2026-2027 XFG) | Type | Minimum age with a qualifying condition |
|---|---|---|
| Pfizer Comirnaty | mRNA | 5 years |
| Moderna Spikevax | mRNA | 6 months |
| Moderna mNEXSPIKE | mRNA | 12 years |
| Novavax Nuvaxovid | protein-based | 12 years |
What the shot buys you, and for how long
Across the previous updated shots (bivalent BA.4/BA.5, XBB.1.5, JN.1, KP.2), protection against hospitalization in adults 65 and older has run roughly 45% to 85% in the first four months, and against death 70% to 95%. The largest recent study, a Danish national cohort of the JN.1-adapted shots in adults over 65, landed near the middle: about 70% against hospitalization and 76% against death, with little waning at four months.
Older adults get most of the benefit because they carry most of the risk. Roughly two-thirds of US COVID hospitalizations still fall on adults 65 and older. Protection against catching the virus at all wanes fast, within three to six months. Protection against severe disease and death holds up longer but also fades, which is why timing the shot before the winter wave matters more than the exact date.
For a healthy 30-year-old with no qualifying condition, the absolute benefit was already small. A US microsimulation estimated an annual booster prevents about 14 severe cases per 100,000 in adults 18 to 49, versus about 199 per 100,000 in adults 75 and older. The label change formalizes what the evidence had been showing. The reason to get boosted is age or a real risk factor, not the calendar.
Where you'll actually have trouble getting one
Not at the FDA. The friction is at the state level. CVS is giving the updated shot without a prescription in about 34 states, but requires one in roughly 16, including Florida, New York, Pennsylvania, Virginia, Georgia, Colorado, and North Carolina. In Massachusetts, Nevada, and New Mexico, CVS can't administer it at all under state pharmacy laws. Walgreens and independent pharmacies follow similar patterns. Call your local pharmacy or check its online scheduler before you drive over. If your state needs a prescription, telehealth is usually the fastest route.
Insurance is the other unknown. ACIP guidance, which normally locks in no-cost coverage under the Affordable Care Act, is under a March 2026 court stay, so coverage isn't automatic in the usual way. The major insurers in AHIP have publicly committed to covering the updated shot through the end of 2027, and Medicare Part B still covers COVID vaccines. Plan-by-plan variation is real, so a quick call to your insurer will tell you whether you're at zero cost or looking at a copay.
What this leaves you with
If you're 65 or older, or under 65 with any of the CDC-listed conditions, the shot's available to you and the evidence still supports it within about four months. The remaining work is procedural: check whether your state needs a prescription, confirm your plan pays, and time it before circulation peaks. If you're a healthy adult under 65 with no qualifying condition, the vaccine isn't approved for you this year, and the absolute benefit in your group was already small. What would change that answer is a randomized trial showing meaningful severe-disease protection in healthy under-65 adults, an updated ACIP recommendation once the court stay lifts, or a formal enforceable FDA list of qualifying conditions.